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In this issue, Janecka and colleagues1 conclude that maternal prenatal use of most medications 
that target specific neurotransmitter systems is not associated with offspring autism. This is a new 
perspective to consider in view of the hypothesis that there could be adverse neurodevelopmental 
effects of prenatal medications affecting serotonergic, GABAergic and glutaminergic 
neurotransmitters. Although results vary,2,3 previous studies have  warned of potential bias arising 
from confounding by maternal indications for prenatal drug treatments which is ‘stubbornly’ 
difficult to resolve.4 Janecka and colleagues grouped medications into classes on the basis of each 
drug’s target neurotransmitter, regardless of the drug’s medical indication, and then estimated 
autism risk associated with maternal use of a drug in a class targeting a common 
neurotransmitter. They called this a ‘biology first’ approach to highlight that their autism risk 
assessment was linked to the drugs’ shared pharmacological effect and functional similarities 
while disassociated from the underlying indication. 
 
The strategy implemented by Janecka and colleagues is intriguing and warrants careful 
consideration. For perspective, we illustrate two approaches to tease out associations among 
medical indications for treatment, drug treatments and outcome. In Figure 1 I., the associations 
with an outcome are compared across different drugs, with potentially different pharmacological 
mechanisms but prescribed for the same medical indication. In this scenario, if the associations 
with the outcome are similar across different drugs (and drug mechanisms) then it suggests 
possible confounding by the underlying medical indication. In contrast, in Figure 1 II.a., the 
associations of drug treatments, prescribed for different medical indications but sharing a 
common pharmacological mechanism, are measured for the same outcome. If associations are 
similar across the treatments, this suggests that the shared pharmacological mechanism, 
regardless of the indication, is the basis for the association between the drugs and the outcome. 
This strategy is consistent with the concept of ‘analogy’ described as the 9th Bradford Hill criterion 
for causal inference with observational data. For example, one could propose to test a mechanism 
underlying an association between a risk factor and outcome on the basis of its analogy to the 
same mechanism for which there is strong causal evidence.5  
 
For the current study, the primary hypothesis that autism may be associated with a perturbed 
neurotransmitter system mechanism during fetal development is based on considerable scientific 
support,6-8 but which has not achieved the level of ‘strong causal evidence’. In fact, this study’s 
largely negative findings could be viewed as evidence against the neurotransmitter mechanism 
hypothesis. One should consider, however, what was tested in the current study. For this study 
(Figure 1 II.b.), all drugs were collapsed into one or more classes, each class sharing a 
neurotransmitter target (labled as Mechanism1 in Figure 1) and the analyis measured the 
association between each mechanism (drug class) and outcome (autism). Thus, all medical 
indications and all prescribed treatments for the indications were collapsed into a single 
mechanism category, making it problematic to tease out the role of confounding by indication, 
particularly where one particular type of drug dominated a category. Furthermore, there is 
potential heterogeneity WITHIN each mechanism category in terms of treatment (e.g., drug dose, 
bioavailability, timing of administration, adverse effects, etc.). For example, some medications, 
although acting on the same neurotransmitter target may be used in very different dosages 
depending on the indication. Some antidepressants are prescribed for neuropathic pain conditions 
and some antipsychotics for hyperemesis gravidarum, but typically at lower dosage for these 
indications than those for their psychiatric indications. It is not possible to gauge how the 
associations estimated in this study may have been impacted by heterogeneity in the actual 
‘exposure’ to drugs in a single class. Ideally, a strategy closer to that illustrated in Figure 1 II.a. 
could tease out the effects of variation in these pharmacological properties and treatments on the 
outcome risk but it is unlikely that the present study had sufficient statistical power to carry out 
such an analysis.  
 
It would be hasty to conclude also, based on this study’s negative findings for specific drug classes, 
that drugs in the class have no associations with autism because there may be other mechanisms 
at play, e.g. valproate may impair fetal neurodevelopment via  inhibition of histone deacetylases 
leading to increases in gene expression. Further, it is important to recognize that a full profile of 
the pharmacological properties of many of the drugs examined in this study is still unknown. 
 
An unexpected finding was the importance of the number of maternal illnesses as a confounder. 
The authors’ acknowledged that the ‘active ingredient’ which explains the confounding 
mechanism of this measure remains unknown. The well recognized high psychiatric and somatic 
comorbidity in persons with autism and risk for autism from high maternal comorbidity as seen in 
this study may actually reflect a common underlying pathogenesis. Thus, it is plausible that the 
importance of the maternal illness variable is an indication that the study strategy did not fully 
account for the complex pathways linking maternal medical indications with autism risk and 
therefore leading to residual confounding in the study results.  
 
Janecka and colleagues acknowledged that their study was exploratory and we agree their results 
should be viewed as such.  Future work could follow their example in suitably powered studies and 
with refinements, as exemplified in Figure 1 to strengthen causal inference. In view of 
heterogeneous results by cognitive ability in autism, this could be best done by examining autism 
subgroups which may differ in their susceptibility to a drug exposure.9  However, no single strategy 
may be enough to account for confounding by indication and, in the absence of randomised 
controlled trials, the above approach may be one of several tools in the epidemiologist’s toolbox 
to seek consistency or ‘triangulation’ of findings across various methods with different strengths 
and limitations.10 
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FIGURE TITLE: Strategies to examine associations among medical indications for treatment, 
treatment and outcome 
 
 
